{"id":"W4410810027","doi":"10.1200/jco.2025.43.16_suppl.tps2687","title":"Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; T-cell receptor; Bifunctional; Antibody; Receptor; Cancer research; Immunology; Pharmacology; Molecular biology; Internal medicine; T cell; Biochemistry; Biology; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001369921,0.001987132,0.001105581,0.0005847329,0.0003703933,0.001105471,0.001081177,0.001566255,0.004819444],"category_scores_gemma":[0.0006829785,0.0006767752,0.001002856,0.0003663644,0.0007849931,0.0009191337,0.0004725861,0.004132576,0.001406659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013289,"about_ca_system_score_gemma":0.001781549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008768836,"about_ca_topic_score_gemma":0.002191953,"domain_scores_codex":[0.9996557,0.0001216578,0.000009831146,0.00006276139,0.00004507967,0.0001050575],"domain_scores_gemma":[0.9996505,0.00004071205,0.00005914153,0.00003544046,0.0000390798,0.0001751549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3352211,0.1764284,0.006264284,0.001052665,0.00103991,0.0007258242,0.0009010058,0.009204656,0.2475937,0.001795625,0.02987378,0.1898989],"study_design_scores_gemma":[0.3506195,0.5955334,0.008782133,0.00008498919,0.0003653555,0.0008407377,0.0001254256,0.004226755,0.02577562,0.0008224636,0.01274584,0.00007761916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785957,0.001693259,0.002629247,0.0009746515,0.0002152572,0.007048152,0.004073169,0.0005402651,0.004230212],"genre_scores_gemma":[0.9497854,0.002651149,0.009039625,0.002369094,0.0002068899,0.01107829,0.01415423,0.0002485471,0.01046679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004819444,"threshold_uncertainty_score":0.0161227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03909459737228007,"score_gpt":0.4344524656994455,"score_spread":0.3953578683271655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}